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Abstract
Helicobacter pylori is a gastrointestinal pathogen known to be associated with cardiovascu-
lar disease (CVD). However, most analyses about the effect of H. pylori infection have
been done in patients with a history of CVD but not in healthy subjects. We evaluated the
association between H. pylori infection and subclinical atherosclerosis by using cardiac mul-
tidetector computed tomography (MDCT) in healthy subjects without previous CVD. From
December 2007 to February 2014, 463 subjects who underwent the rapid urease test (CLO
test), pulse-wave velocity (PWV) measurement, and MDCT for a self-referred health check-
up were enrolled to this study. Helicobacter pylori infection was defined on the basis of CLO
test positivity on endoscopic gastric biopsy. Significant coronary artery stenosis was defined
as50% stenosis in any of the major epicardial coronary vessel on MDCT. The CLO-posi-
tive subjects had a lower high-density lipoprotein-cholesterol (HDL-cholesterol) level com-
pared to the CLO-negative subjects. The incidence of significant coronary stenosis was
higher in the CLO-positive group (7.6% vs. 2.9%, P = 0.01). Furthermore, the number of sub-
jects with coronary artery calcium score >0 and log{(number of segments with plaque)+1}
were also significantly higher in the CLO-positive group. However, there was no statistical
difference in the number of subjects with coronary artery calcium score >100, the prevalence
of any plaque nor the plaque characteristics (calcified, mixed, or soft). Pulse-wave velocity
(PWV) was neither associated with CLO test positivity. The CLO-positive group was 3-fold
more likely to have significant coronary artery stenosis even after adjusting for confounding
factors (adjusted odds ratio 2.813, 95% confidence interval 1.051–7.528, P = 0.04). In a
healthy population, current H. pylori infection was associated with subclinical but significant
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coronary artery stenosis. The causal relationship between H. pylori infection and subclinical
atherosclerosis in a “healthy” population remains to be investigated in the future.
Introduction
Several studies have reported that cardiovascular disease (CVD) may be associated with certain
microorganisms such as Chlamydia pneumonia, cytomegalovirus, or Helicobacter pylori [1].
Those reports have suggested that the pathogens might directly invade the vessel wall, leading
to localized vascular inflammation [2]. Additionally, not only localized but also systemic
inflammation by such pathogens might indirectly induce endothelial dysfunction and dyslipi-
demia, resulting in CVD [3].
Helicobacter pylori is a gram-negative bacterium that lives in the stomach and a carcinogen
leading to stomach cancer [4,5]. The infection rate of H. pylori is especially high in Asians [6].
Because local and systemic inflammation by microbes and infectious agents is known to be
crucial in CVD [7,8], the relationship between H. pylori infection and CVD has received con-
siderable attention especially in Asian countries [9–12].
H. pylori has been suggested as a possible contributor to CVD progression but the results
from the previous studies were quite controversial. Some reports showed that the seropreva-
lence of H. pylori was not correlated with coronary artery disease and they insisted that the
infection status of H. pylori did not determine the risk of CVD [13–16]. In contrast, other
reports demonstrated a meaningful higher prevalence of H. pylori infection among patients
with previous history of CVD and supported a possible connection between H. pylori and the
development of CVD [12,17–21]. In healthy populations without previous CVD, however, it
still remains unclear whether H. pylori infection is significantly associated with subclinical ath-
erosclerosis. The individuals with subclinical atherosclerosis are at a higher risk of developing
clinical atherosclerosis including coronary heart disease compared to the individuals without
subclinical diseases [22–24]. If the association between H. pylori and subclinical atherosclerosis
is significant, earlier diagnosis and possibly eradication of H. pylori might be necessary for pre-
venting atherosclerosis progression, especially in the high-risk population. Additionally, most
studies on H. pylori infection and CVD have relied on antibody tests for defining the H. pylori
infection status [17,18,20], the results of which cannot differentiate between current versus
past infections. Additionally, tests using the serum antibodies demonstrate lower specificity
than that of the rapid urease test (CLO test) [25,26].
In this study, we aimed to evaluate whether current H. pylori infection, diagnosed by using
an endoscopic CLO test, was associated with subclinical atherosclerosis using pulse-wave
velocity (PWV) and cardiac multidetector computed tomography (MDCT) in a healthy
population.
Methods
Study design and population
This study included 527 consecutive subjects undergoing esophagogastroduodenoscopy with
the CLO test, PWV, and MDCT as part of the self-referred health check-up program at Gang-
nam Severance Hospital Health Promotion Center, Seoul, Korea from December 2007 to
February 2014. All participants were divided into two study groups according to the CLO
positivity. To avoid confounding bias, we excluded possible confounding medical conditions
known to be associated with the health outcome. The exclusion criteria were as follows: (i)
Helicobacter and subclinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0193646 March 2, 2018 2 / 13
history of coronary artery disease, (ii) significant hypothyroidism/hyperthyroidism (thyroid-
stimulating hormone >4.5 μIU/mL or free thyroxine >2.0 ng/dL), (iii) significant renal insuf-
ficiency (creatinine >1.5 mg/dL), (iv) significant CRP (C-reactive protein) elevation (>10.0
mg/L) and (v) subjects with any GI (gastrointestinal) medications. Since we intended to inves-
tigate the association between H. pylori infection and subclinical atherosclerosis in healthy
population, subjects with previous coronary artery disease were excluded. Subjects with thy-
roid dysfunction and renal insufficiency were omitted as changes in thyroid or renal function
influence the level of serum lipids along with coronary atherosclerosis [27–29]. We excluded
the subjects with elevated CRP levels as various pro-inflammatory conditions and diseases can
affect the progression of atherosclerosis [30,31]. We further excluded the subjects taking GI
medications for gastritis or gastric ulcer. Finally, 463 participants were included in the current
analysis (Fig 1). The protocol of this study was approved by the institutional review board of
Gangnam Severance Hospital.
Anthropometric and biochemical measurements
We reviewed the participants’ questionnaire at the time of the health check-up, which included
medical history, concomitant medication use, and other medico-social history information.
After an overnight fasting for8 hours, the fasting plasma glucose, total cholesterol, HDL-
Fig 1. Schematic diagram and overall flow of study participants. Abbreviations: CLO test, rapid urease test; cardiac MDCT, cardiac multidetector computed
tomography; PWV, pulse-wave velocity; CVD, cardiovascular disease; TFT, thyroid function test; Cr, creatinine; CRP, C-reactive protein; GI medications,
gastrointestinal medications.
https://doi.org/10.1371/journal.pone.0193646.g001
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cholesterol, triglyceride, calcium, and C-reactive protein levels were checked from the periph-
eral venous blood samples by means of adequate enzymatic methods (Hitachi 7600–120 auto-
mated chemistry analyzer; Hitachi, Tokyo, Japan). The Friedewald formula was used to
calculate the low-density lipoprotein-cholesterol (LDL-cholesterol) level.
Coronary artery calcium score, coronary artery stenosis, and coronary
plaque measurement with MDCT
Coronary artery calcium scores (CACSs), coronary artery stenosis, and the number, presence
and the characteristics of intracoronary plaques were evaluated by using an MDCT scanner
(Philips Brilliance 64; Philips Medical System, Best, the Netherlands). A standard prospective
electrocardiogram-gating protocol with a step-and-shoot technique (64 × 0.625 mm slice sec-
tion collimation, 420-ms rotation time, 120-kV tube voltage, and 210-mAs tube current) was
used. The CACS was measured (Extended Brilliance Workspace BW V4.5.2.4031, Philips
Medical System) and described as Agatston scores. The CACS was interpreted as having either
no coronary calcium (CACS 0 vs.>0) or severe coronary calcium (CACS100 vs.>100).
Coronary arteries were segmented to 3 major arteries and 12 small branches. Significant coro-
nary artery stenosis was defined as at least50% stenosis in any coronary artery/branch. A
plaque was defined as a structure >1 mm2 within and/or adjacent to the vessel lumen, and
classified according to the presence/proportion of intraplaque calcification. The plaques were
divided into calcified (calcium [>130 Hounsfield units] content50% of the whole plaque),
mixed (calcium content<50% of the whole plaque) or soft (no calcium content). Log{(number
of segments with plaque) + 1} was used to analyze the number of segments with plaque.
Pulse-wave velocity
Brachial-ankle PWV (ba-PWV) was assessed by using a volume plethysmographic instrument
(VP-1000; Omron Healthcare Corporation, Kyoto, Japan). The ba-PWV was estimated as
the value of brachial-ankle distance divided by the blood transit time. An automatic device
recorded electrocardiograms, phonocardiograms and the blood pressure (BP) at both the bra-
chial artery and the posterior tibial artery after a stable rest for5 min in supine position. The
average value of the right and left sides was defined as the mean PWV.
Rapid urease test
Biopsy of the gastric mucosa was performed to assess the H. pylori infection status with a com-
mercial CLO kit (ASAN Pharm. Co., Seoul, Korea). Each gastric mucosal biopsy specimen was
immediately transferred into the CLO kit and analyzed after 30 min of reaction to determine
the test positivity according to the color change of the reaction kit.
Statistical analyses
Continuous variables with normal distribution are presented as mean ± standard error (SE),
and those with a skewed distribution, such as CACS or the number of coronary segments with
any plaque, were log transformed for analyses. Categorical variables are presented as absolute
numbers and percentages. Intergroup comparisons with age adjustment were performed by
using analysis of covariance for continuous variables and the generalized estimating equation
for categorical variables. Adjusted odds ratios (ORs) for significant coronary artery stenosis in
the CLO-positive group compared with the negative group were estimated with logistic regres-
sion analysis models. The SPSS statistical package (version 20.0; SPSS Inc., Chicago, IL, USA)
was used for all statistical analyses. A P-value of0.05 was considered statistically significant.
Helicobacter and subclinical atherosclerosis
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Results
Clinical and biochemical characteristics of the study population
A total of 463 subjects (336 men, 127 women, mean age 54.2 ± 8.5 years) were analyzed for the
current study and divided into two groups according to the CLO test result. There were 224
(48.4%) CLO-positive and 239 (51.6%) CLO-negative subjects, respectively. The clinical and
biochemical characteristics of the study subjects are presented in Table 1. The minimum and
maximum age of this whole study population was 31 and 80 years, respectively (33–80 years
for the CLO-negative group; and 31–77 years for the CLO-positive group). The mean age was
different between the two groups (53.2 ± 7.9 years for the CLO-positive group vs. 55.3 ± 8.9
years for the CLO-negative group, P = 0.01). Therefore, comparisons throughout this study
were performed after adjustment for age as a confounding variable. The CLO-positive group
had a lower mean HDL-cholesterol level (46.6 ± 0.8 mg/dL vs. 49.6 ± 0.8 mg/dL, P = 0.01) and
a higher mean triglyceride level (134.5 ± 5.7 mg/dL vs. 116.4 ± 5.5 mg/dL, P = 0.02). There
were no differences in the prevalence of diabetes and hypertension nor the use of antidiabetic,
antihypertensive, and antiplatelet agents between the two groups. Subjects in the CLO-positive
group were more likely to take a lipid-lowering agent compared to those in the CLO-negative
group (15.6% vs. 10.5%, P = 0.05).
Table 1. Clinical and biochemical characteristics of study subjects with age adjustment.
Total
N = 463
CLO-negative
N = 239
CLO-positive
N = 224
P-value
Demographics
Age (yr) 54.2 ± 8.5 55.3 ± 8.9 53.2 ± 7.9 0.01
minimum and maximum 31–80 33–80 31–77
Male (N, %) 336 (72.6) 165 (69.0) 171 (76.3) 0.07
Hypertension (N, %) 213 (46.0) 113 (47.3) 100 (44.6) 0.89
Diabetes (N, %) 79 (17.1) 39 (16.3) 40 (17.9) 0.35
Diabetes medication (N, %) 46 (9.9) 27 (11.3) 19 (8.5) 0.58
Lipid lowering agent (N, %) 60 (13.0) 25 (10.5) 35 (15.6) 0.05
Antiplatelet agent (N, %) 76 (16.4) 42 (17.6) 34 (15.2) 0.84
Anthropometrics
Systolic BP (mmHg) 128.2 ± 16.7 128.2 ± 1.1 128.2 ± 1.1 0.97
Diastolic BP (mmHg) 80.1 ± 9.9 79.8 ± 0.6 80.4 ± 0.7 0.51
BMI (Kg/m2) 24.3 ± 3.1 24.1 ± 0.2 24.5 ± 0.2 0.26
Laboratory indices
Fasting glucose (mg/dL) 100.6 ± 24.8 98.9 ± 1.6 102.5 ± 1.7 0.12
Total cholesterol(mg/dL) 191.3 ± 36.3 193.2 ± 2.3 189.3 ±2.4 0.25
Triglyceride (mg/dL) 125.2 ± 84.8 116.4 ± 5.5 134.5 ± 5.7 0.02
HDL-cholesterol (mg/dL) 48.2 ± 12.5 49.6 ± 0.8 46.6 ± 0.8 0.01
LDL-cholesterol (mg/dL) 116.8 ± 32.9 119.1 ± 2.1 114.3 ± 2.2 0.12
Calcium (mg/dL) 9.1 ± 0.52 9.1 ± 0.03 9.0 ± 0.03 0.37
CRP (mg/L) 1.2 ± 1.32 1.2 ± 0.09 1.2 ± 0.09 0.77
BP, blood pressure; BMI, body mass index; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low density lipoprotein-cholesterol; CRP, C-reactive
protein; DM, diabetes mellitus. A one-way analysis of variance was used to evaluate the difference of continuous variables between CLO positive and negative subjects
with age adjustment. The generalized estimating equation was used to compare categorical variables between the CLO positive and negative groups with age adjustment.
Continuous variables are presented as mean±standard error or the value of minimum and maximum. Dichotomous variables are presented as the number of subjects
with the percentage of subjects in the parenthesis. P < .05 was regarded as statistically significant.
https://doi.org/10.1371/journal.pone.0193646.t001
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Differences in PWV, CACS, and incidence of coronary stenosis/
intracoronary plaque between the CLO-positive versus the CLO-negative
subjects
The presence of coronary artery calcium (CACS >0) was significantly higher in the CLO-posi-
tive group (36.7% vs. 32.5%, P = 0.05) than in the CLO-negative group. However, there were
no statistical differences in the presence of severe coronary artery calcium (CACS >100), the
mean value of log(CACS + 1) or the mean PWV between the CLO-positive and CLO-negative
subjects. There was also no difference between the two groups not only in the prevalence of
any plaque but also in the characteristics of plaque (calcified, mixed, or soft). However, the
number of segments with plaque was higher in the CLO-positive group (0.22 ± 0.02 vs.
0.17 ± 0.02, P = 0.03). More importantly, the incidence of significant coronary artery stenosis
(50% stenosis of any major vessel) was significantly higher in the CLO-positive subjects than
in the CLO-negative subjects (7.6% vs. 2.9%, P = 0.01) (Table 2).
Elevated adjusted risk for significant coronary artery stenosis in CLO-
positive subjects
To investigate whether current H. pylori infection is an independent risk factor for subclinical
atherosclerosis, we evaluated the adjusted risk for significant coronary artery stenosis in the
CLO-positive subjects compared with the CLO-negative subjects by analyzing odds ratio
(Table 3 and Fig 2). The CLO-positive subjects were 2.72-fold more likely to have significant
coronary artery stenosis compared to the CLO-negative subjects. This risk became more sig-
nificant after adjusting for age and sex (adjusted OR 3.431, 95% confidence interval 1.343–
8.765, P = 0.01) and also after adjusting for several additional factors that may influence
coronary artery stenosis, such as systolic blood pressure (BP), fasting glucose, HDL-choles-
terol, anti-hypertension/diabetic medications, lipid-lowering agents, and antiplatelet agents
(adjusted OR 2.813, 95% confidence interval 1.051–7.528, P = 0.04).
Table 2. Difference of subclinical atherosclerosis between the CLO-negative and CLO-positive subjects with age adjustment.
Total
N = 463
CLO-negative
N = 239
CLO-positive
N = 224
P-value
PWV (cm/s) 1422.4 ± 234.3 1419.9 ± 13.1 1425.0 ± 13.5 0.79
CACS
CACS >0 (n, %) 157 (34.5) 76 (32.5) 81 (36.7) 0.05
CACS >100 (n, %) 51 (11.2) 27 (11.5) 24 (10.9) 0.49
Log (CACS +1) 0.57 ± 0.87 0.51 ± 0.05 0.64 ± 0.05 0.08
Plaque
Any plaque (%) 104 (22.5) 52 (21.8) 52 (23.2) 0.32
Log{(Number of segments with plaque)+1} 0.20 ± 0.26 0.17 ± 0.02 0.22 ± 0.02 0.03
Calcified plaque (%) 58 (12.5) 29 (12.1) 29 (12.9) 0.38
Mixed plaque (%) 41 (8.9) 19 (7.9) 22 (9.8) 0.25
Soft plaque (%) 32 (6.9) 17 (7.1) 15 (6.7) 0.99
Coronary artery stenosis (n, %) 24 (5.2) 7 (2.9) 17 (7.6) 0.01
PWV, pulse-wave velocity; CACS, coronary artery calcium score. A one-way analysis of variance was used to evaluate the difference of PWV or number of coronary
segments involved between CLO negative and positive subjects with age adjustment. The generalized estimating equation was used to evaluate the difference of
dichotomous variables between the two groups with age adjustment. Continuous variables are presented as mean±standard error. Dichotomous variables are presented
as the number of subjects with the percentage of subjects in the parenthesis. P < .05 was regarded as statistically significant.
https://doi.org/10.1371/journal.pone.0193646.t002
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Discussion
In this study, we demonstrated that current H. pylori infection is significantly associated with
significant coronary artery stenosis in a healthy population. The elevated risk of coronary
artery stenosis in H. pylori-infected subjects was associated with a lower HDL-cholesterol level.
This is the first report demonstrating that active/current H. pylori infection can be a risk for
subclinical atherosclerosis in healthy subjects without previous CVD.
Table 3. Odds ratio for significant coronary artery stenosis.
Odds ratio (95% CI) P-value
CLO-negative
N = 239
CLO-positive
N = 224
Model 1 1.000 (reference) 2.722 (1.107–6.694) 0.03
Model 2 3.431 (1.343–8.765) 0.01
Model 3 3.330 (1.285–8.629) 0.01
Model 4 2.813 (1.051–7.528) 0.04
Model 1: Not adjusted
Model 2: adjusted for age and sex
Model 3: adjusted for age, sex, HDL-cholesterol
Model 4: adjusted for age, sex, systolic BP, fasting glucose, HDL-cholesterol, anti-hypertension medication, anti-
diabetic medication, lipid lowering agent, anti-platelet agent
CI, confidence interval; BP, blood pressure; HDL-cholesterol, high density lipoprotein-cholesterol. Data are
presented as odds ratios with the CLO-negative group as a reference.
https://doi.org/10.1371/journal.pone.0193646.t003
Fig 2. Odds ratio for significant coronary artery stenosis according to the CLO test. Logistic regression was used
for calculating odds ratios with 95% confidence intervals. The reference group comprised the CLO-negative subjects.
Model 1: Not adjusted
Model 2: adjusted for age and sex
Model 3: adjusted for age, sex, HDL-cholesterol
Model 4: adjusted for age, sex, systolic BP, fasting glucose, HDL-cholesterol, anti-hypertension medication, anti-dia-
betic medication, lipid lowering agent, anti-platelet agent
Abbreviations: OR, odds ratio; CI, confidence interval; BP, blood pressure; HDL-cholesterol, high density lipoprotein-
cholesterol.
https://doi.org/10.1371/journal.pone.0193646.g002
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The diagnostic tests for H. pylori can be divided into invasive and noninvasive methods.
The serologic H. pylori IgG test, urea breath test, and stool antigen assay are noninvasive,
whereas the CLO test can only be performed with stomach tissue obtained from invasive endo-
scopic biopsy [25]. As the serologic H. pylori IgG test is fast, cheap, and noninvasive, most of
the studies on H. pylori infection and CVD were performed using this test [17,18,20,32–35].
However, conflicting results exist between the serology and the prevalence of CVD, with
some studies showing a significant association between H. pylori seropositivity and CVD
[12,17,18,20,32] while others showing no such association [33–35]. One of the possible reasons
for these conflicting results may be certain limitations of the serologic test in detecting H.
pylori infection itself [36]. Most importantly, serologic antibody testing cannot distinguish cur-
rent and past infection.[26] Owing to this limitation, the serologic test has been mostly used to
investigate merely the association between the prevalence of H. pylori infection and CVD
[18,32,37]. In contrast, a positive CLO test means a current infection [26]. If current H. pylori
infection is associated with subclinical atherosclerosis, it can be inferred that the eradication of
H. pylori infection might help prevent the progression of atherosclerosis. In this context, this
study provides a theoretical basis for studying the effect of H. pylori eradication on preventing
the future progression of atherosclerosis.
However, the CLO test is not without limitations. For example, although atrophic gastritis
is explicitly associated with H. pylori in many cases, the CLO test may fail to detect the presence
of H. pylori because of a decreased bacterial burden in atrophic gastritis, particularly in the
presence of intestinal metaplasia [26]. Nevertheless, the CLO test can provide more accurate
and reliable results than the serologic test [25]. The specificity of the CLO test is 95–100%,
whereas the serologic test has variable specificity ranging from 76% to 96% [25]. Moreover, the
CLO test has a higher sensitivity (80–95%) than the serologic test (75–85%) [26]. Hence, our
data provide more accurate evidence for examining the association between H. pylori infection
and CVD compared with previous studies with the serologic test.
Several studies have reported the correlation between the prevalence of H. pylori infection
and overt coronary artery disease [11,17–21]. However, no study has demonstrated the associ-
ation between current H. pylori infection and subclinical coronary atherosclerosis. This study
is distinct from previous studies because we did not observe CVD events but the incidence of
subclinical coronary atherosclerosis in a relatively large number of healthy subjects without
previous CVD. Atherosclerosis is a pathologic process narrowing the coronary, cerebral, and
peripheral arteries due to the formation of atheromatous plaques [38]. Studying the association
between H. pylori infection and subclinical atherosclerosis allows investigators to confirm that
earlier vessel-wall changes can be induced by H. pylori infection. Some reports have shown
the association between H. pylori infection and the degree of carotid atherosclerosis, but not
with that of coronary atherosclerosis [39–41]. To our knowledge, this is the first study that
employed the CLO test to detect current H. pylori infection, and linked this test with direct
visualization of the coronary artery with cardiac MDCT in a relatively large number of healthy
subjects. The significant correlation between H. pylori infection and subclinical coronary ath-
erosclerosis in this study might be able to support H. pylori eradication as a potential cardio-
vascular prevention strategy.
How H. pylori infection can induce atherosclerosis has not been clearly established yet
[10,29]. In this study, HDL-cholesterol was lower and triglyceride was higher in the CLO-posi-
tive group. Some data suggest that dysregulated lipid metabolism, including a low HDL-cho-
lesterol level, may accelerate atherosclerosis in patients with H. pylori infection [10,42–45].
Helicobacter pylori carries lipopolysaccharide and can upregulate certain cytokines in the host,
such as tumor necrosis factor-α (TNF-α) [9,10,35]. Inhibition of lipoprotein lipase by cyto-
kines, such as TNF-α, may mobilize lipids from the tissues [46], leading to low serum HDL-
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cholesterol levels [47]. Besides perturbing the lipid metabolism, H. pylori infection may also
directly induce atherosclerosis. Endothelial dysfunction induced by vacuolating cytotoxin
A secreted from H. pylori [48,49], molecular mimicry by the autoimmune response [50],
enhanced systemic inflammation [51], oxidative stress [52], and platelet aggregation [53] by H.
pylori are all potential mechanisms of atherosclerosis that have been reported to be directly
induced by H. pylori infection. The possibility of H. pylori induced-atherosclerosis indepen-
dent of HDL-cholesterol levels is also supported by our data showing that H. pylori itself is
associated with a higher incidence of significant coronary artery stenosis despite adjusting for
HDL-cholesterol level. This significant association between H. pylori and significant coronary
artery stenosis, irrespective of disturbed HDL-cholesterol levels, suggests that H. pylori infec-
tion may aggravate coronary atherosclerosis through both lipid metabolism-dependent and
independent pathways.
CACS has also been used for suggesting the association between H. pylori seropositivity and
coronary atherosclerosis. In a previous study, the degree of coronary atherosclerosis assessed
by CACS was significantly associated with H. pylori seropositivity [32]. In our study, the pres-
ence of coronary artery calcium (CACS >0) was significantly higher in the CLO-positive
group. On the other hand, there were no statistical differences in the presence of severe coro-
nary artery calcium (CACS >100) and the mean value of log(CACS + 1) between the CLO-
positive and CLO-negative subjects. Considering that CACS is more specific in subjects older
than 60 years [54,55], the relationship between CACS and H. pylori infection needs to be fur-
ther investigated in a larger study population.
The link between H. pylori infection and increased arterial PWV has been documented pre-
viously [56,57]. As chronic H. pylori infection is thought to induce systemic inflammation
through cytokines such as interleukin-6 [44,51], not only coronary but also peripheral vascular
changes can occur [58]. However, the mean PWV was not different according to the CLO
positivity in our study. These inconsistent results may possibly be because of the differences
in the PWV measurement sites (heart-carotid vs. brachial-ankle) and differences in the study
population, as well as the diagnostic tool for H. pylori infection [56,57]. In addition, consider-
ing the previous reports that bacterial DNA of H. pylori was identified in coronary atheroscle-
rotic plaque [10,59,60], H. pylori might be able to aggravate coronary atherosclerosis by direct
invasion into the coronary vessels preferentially compared to other vessels regardless of sys-
temic inflammation.
Our study has several limitations. First, this study lacks the measurement of cytotoxin-asso-
ciated gene-A (CagA), which has been known to determine the pathogenicity of H. pylori in
atherosclerosis [61–63]. It would be necessary to investigate this in future studies. Other limita-
tions of this study are characteristics of the study population. As Gangnam Severance hospital
is located in an affluent part of the capital city, the demographic and the socio-economic char-
acteristics might be different from the general population. The individuals in our study popu-
lation were more likely to be male, aged and upper white-collar workers prominently [64,65].
Lastly, we could not discriminate the subjects who had H. pylori eradication treatment previ-
ously because this was not included in the questionnaire of the health check-up. Nevertheless,
our study is powerful and unique in demonstrating the association between subclinical athero-
sclerosis and H. pylori infection compared to other studies because our dataset is composed of
extensive data encompassing MDCT, PWV, and CLO-test, the results of which are difficult to
gather comprehensively.
In conclusion, current H. pylori infection is associated with subclinical but significant coro-
nary artery stenosis in a healthy population. This result suggests the possibility that H. pylori
eradication might be worthwhile in preventing coronary artery disease. Further studies are
warranted to investigate whether CLO test positivity could be a new marker for the assessment
Helicobacter and subclinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0193646 March 2, 2018 9 / 13
of future coronary artery disease risk and the underlying mechanism of how H. pylori infection
may lead to coronary atherosclerosis.
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